Background: Cardiovascular outcomes in clinical trials with type 2 diabetes mellitus (T2DM) patients have shown that glucagon-like peptide-1 receptor agonist can have a beneficial effect on the kidney. This trial aimed to assess the effects of exenatide on renal outcomes in patients with T2DM and diabetic kidney disease (DKD).
Methods: We performed a randomized parallel study encompassing 4 general hospitals. T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) >0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine (control group) for 24 weeks. The primary outcome was the UAER percentage change from the baseline after 24 weeks of intervention. The rates of hypoglycemia, adverse events (AEs), and change in eGFR during the follow-up were measured as safety outcomes.
Results: Between March 2016 and April 2019, 92 patients were randomized and took at least 1 dose of the study drug. The mean age of the participants was 56 years. At baseline, the median UAER was 1,512.0 mg/24 h and mean eGFR was 70.4 mL/min/1.73 m2. After 24 weeks of treatment, the UAER percentage change was significantly lower in the intervention group than in the control group (p = 0.0255). Moreover, the body weight declined by 1.3 kg in the intervention group (the difference between the 2 groups was 2.7 kg, p = 0.0001). Compared to the control group, a lower frequency of hypoglycemia and more gastrointestinal AEs were observed in the intervention group.
Conclusion: Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677996 | PMC |
| http://dx.doi.org/10.1159/000510255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of the Potential Clinical and Economic Impact of Weight Loss in the Adult Population with Obesity and Associated Comorbidities in Spain.
Adv Ther
January 2025
Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge-IDIBELL, C/de la Feixa Llarga S/N, 08907, Hospitalet de Llobregat, Barcelona, Spain.
Introduction: Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.
View Article and Find Full Text PDFPro-Arg, The Potential Anti-Diabetes Peptide, Screened from Almond by In-Silico Analysis.
Plant Foods Hum Nutr
January 2025
College of Biology and Food Engineering, Chongqing Three Gorges University, Chongqing, 404100, China.
Insulin resistance was considered to be the most important clinical phenotype of type 2 diabetes (T2DM). Almond is a widely-consumed nut and long-term intake was beneficial to alleviating insulin resistance in patients with T2DM. Hence, screening of anti-diabetic peptides from almond proteins was feasible based on the effectiveness of peptides in the treatment of T2DM.
View Article and Find Full Text PDFImpact of a multidisciplinary diabetes care programme on glycaemic and metabolic outcomes in regional and First Nations communities: a retrospective observational study.
Intern Med J
January 2025
Mackay Health and Hospital Service, Townsville, Queensland, Australia.
Background: Type 2 diabetes mellitus (T2DM) poses a significant public health challenge in Australia, particularly among underserved populations such as First Nations people and rural communities. In response, the Together Strong Connected Care (TSCC) programme was developed to address these disparities by offering a culturally appropriate, multidisciplinary approach to diabetes management in a regional hospital setting.
Aims: The aim of the study was to assess the impact of the TSCC programme on glycaemic and metabolic control in people living with diabetes.
The incremental value of aspartate aminotransferase/alanine aminotransferase ratio combined with CURB-65 in predicting treatment outcomes in hospitalized adult community-acquired pneumonia patients with type 2 diabetes mellitus.
BMC Pulm Med
January 2025
Department of Public Health, People's Hospital of Nanchuan, Chongqing, 408400, People's Republic of China.
Background: The features of community-acquired pneumonia (CAP) patients with type 2 diabetes mellitus (T2DM) differ from those without. This study aims to spot a routinely tested parameter with discriminative, predictive and prognostic value to enhance CURB-65's prognostic accuracy in CAP patients with T2DM.
Methods: We retrospectively studied consecutive CAP patients from 2020 to 2021, comparing laboratory parameters between patients with and without T2DM.
Diabetic microvascular complications are associated with left ventricular hypertrophy in patients with type 2 diabetes mellitus.
J Diabetes Complications
December 2024
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China; Beijing Key Laboratory of Diabetes Research and Care, Beijing 101149, China. Electronic address:
Background: Left ventricular hypertrophy (LVH) is an important and common pathologic change in the heart of patients with diabetes mellitus. Microvascular complications have been reported to be involved in the development and process of LVH. This study aimed to explore the association between diabetic microvascular complications and LVH in patients with type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!